Statements (60)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:Company
|
gptkbp:acquisition |
gptkb:Tissue_Regenix_Wound_Care
|
gptkbp:awards |
industry awards
|
gptkbp:ceo |
gptkb:Antony_Odell
|
gptkbp:clinical_trial |
ongoing
|
gptkbp:clinical_use |
trauma care
nerve repair vascular repair chronic wounds cartilage repair skin regeneration surgical reconstruction soft tissue repair bone repair musculoskeletal repair |
gptkbp:collaboration |
healthcare providers
|
gptkbp:community_engagement |
awareness campaigns
health education patient support programs |
gptkbp:employees |
50-100
|
gptkbp:financial_performance |
publicly traded
|
gptkbp:focus |
tissue regeneration
|
gptkbp:focus_area |
orthopedics
sports medicine wound care cardiovascular |
gptkbp:founded |
gptkb:2006
|
gptkbp:funding |
grants
investments partnerships |
gptkbp:goal |
improve patient outcomes
|
gptkbp:headquarters |
gptkb:York,_England
|
https://www.w3.org/2000/01/rdf-schema#label |
Tissue Regenix Group
|
gptkbp:impact |
global health
|
gptkbp:industry |
gptkb:health_services
|
gptkbp:innovation |
tissue engineering
|
gptkbp:invention |
multiple patents
|
gptkbp:investment |
institutional investors
|
gptkbp:market |
global
|
gptkbp:mission |
advance regenerative medicine
|
gptkbp:partnership |
gptkb:NHS
research institutions |
gptkbp:products |
Regenerative medicine products
|
gptkbp:regulatory_compliance |
gptkb:CE_mark
|
gptkbp:research_and_development |
biomaterials
|
gptkbp:services |
surgical products
|
gptkbp:strategic_goals |
increase market share
develop new technologies enhance research capabilities expand product line |
gptkbp:supply_chain |
local suppliers
sustainable sourcing global suppliers |
gptkbp:sustainability |
biodegradable materials
|
gptkbp:technology |
decellularization
|
gptkbp:traded_on |
gptkb:AIM
|
gptkbp:vision |
leader in regenerative solutions
|
gptkbp:website |
www.tissueregenix.com
|
gptkbp:bfsParent |
gptkb:Smith_&_Nephew
|
gptkbp:bfsLayer |
5
|